| Filed On | Filing |
|---|---|
| 10 Nov 2026 | 10-Q |
| 10 Nov 2026 |
8-K: Results of Operations and Financial Condition
– Company plans to initiate Phase 3 trials in both severe asthma and CRSwNP in the first quarter of 2027 – |
| 06 Nov 2026 | SCHEDULE 13G/A |
| 29 Oct 2026 | SCHEDULE 13G/A |
| 17 Sep 2026 |
Form 4: Gray Michael, CFO and COO
Sold 853 shares ($4.68K) |
| 17 Sep 2026 |
Form 4: Ambrose Allison, General Counsel
Sold 485 shares ($2.66K) |
| 17 Sep 2026 |
Form 4: Deykin Aaron, Chief Medical Officer
Sold 895 shares ($4.91K) |
| 17 Sep 2026 |
Form 4: Sutherland Everett Rand, Director
Sold 2,095 shares ($11.5K) |
| 17 Sep 2026 |
Form 4: Houghton Adam, Chief Business Officer
Sold 700 shares ($3.84K) |
| 01 Sep 2026 |
8-K: Regulation FD Disclosure; Other Events
– Following productive FDA discussions, Upstream Bio will study 400mg of verekitug administered every 12 weeks, versus placebo, in severe asthma and CRSwNP with one pivotal Phase 3 trial in each indication – |
| 12 Aug 2026 | SCHEDULE 13G/A |
| 11 Aug 2026 | 10-Q |
| 11 Aug 2026 |
8-K: Results of Operations and Financial Condition
– Company rapidly advancing toward Q1 2027 initiation of Phase 3 trials designed to deliver best-in-class efficacy with convenient quarterly dosing in both severe asthma and CRSwNP; End-of-Phase 2 interactions with FDA on track– |
| 30 Jul 2026 | SCHEDULE 13G |
| 17 Jun 2026 |
Form 4: Gray Michael, CFO and COO
Sold 853 shares ($5.2K) |
| 17 Jun 2026 |
Form 4: Sutherland Everett Rand, Director
Sold 2,095 shares ($12.8K) |
| 17 Jun 2026 |
Form 4: Houghton Adam, Chief Business Officer
Sold 700 shares ($4.27K) |
| 17 Jun 2026 |
Form 4: Deykin Aaron, Chief Medical Officer
Sold 895 shares ($5.46K) |
| 17 Jun 2026 |
Form 4: Ambrose Allison, General Counsel
Sold 477 shares ($2.91K) |
| 11 Jun 2026 |
Form 4: Ruddy Marcella K., Director
Granted 17,096 Stock Option (Right to Buy) |
Loading...